Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
AgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
Q1 2026 revenue beat, raised revenue guidance, and the first sixth-generation 256-qubit system sale. The proof gate is RPO conversion, organic revenue growth, and adjusted EBITDA loss discipline.
Redwire has fresh space and drone headlines, but the real RDW proof gate is whether record backlog converts into profitable revenue and cash without new dilution pressure.
Rubrik reported FY2026 revenue of $1.3 billion, FY2026 operating cash flow of $282.9 million, a FY2026 net loss of $348.8 million and $380.2 million of cash. The thesis depends on subscription durability, data security demand, operating leverage, cash conversi
Q2 Holdings reported FY2025 revenue of $794.8 million, Q1 2026 revenue of $216.5 million, FY2025 operating cash flow of $201.5 million and Q1 2026 net income of $26.6 million. The thesis depends on banking software demand, subscription durability, margin expan
Okta reported FY2026 revenue of $2.9 billion, FY2026 operating income of $149 million and FY2026 operating cash flow of $884 million. The thesis depends on identity demand, retention, remaining performance obligations, margin discipline and security-platform c
A Coverage Bootstrap Microsoft company evaluation covering Azure, Microsoft 365, Copilot, AI capex, enterprise distribution, security, gaming, regulation, and valuation setup.
Hims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.
GitLab reported FY2026 revenue of $955.2 million, gross profit of $834.5 million, operating loss of $70.5 million and operating cash flow of $232.9 million. The setup depends on DevSecOps adoption, platform consolidation, gross-margin durability, operating dis
Hims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
Enphase reported Q1 2026 results and announced an IQ solid-state transformer program for AI data centers. The proof gate is revenue stabilization, battery shipments, non-GAAP gross margin, and IQ SST progress.
BitMine priced an upsized preferred-stock deal, and the real question is whether ETH treasury growth can beat a new preferred dividend claim that sits ahead of common shareholders.
BMNR said crypto plus cash plus other holdings totaled twelve point three billion dollars as of May 25, 2026. The proof gate is ETH per share, staking yield, cash runway, and NAV transparency.